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CASE REPORT
Alveolar rhabdomyosarcoma confined 
to the bone marrow with no identifiable 
primary tumour using FDG-PET/CT
Panagiotis Karagiannis1,2*†, Nina Guth1†, Gabriela B. Thoennissen1, Christina Bern3, Jan Sperveslage4, 
Ilske Oschlies5, Carsten Bokemeyer1, Wolfram Klapper5, Eva Wardelmann4 and Nils H. Thoennissen1
Abstract 
Background: Rhabdomyosarcoma (RMS), a malignant tumour of mesenchymal origin which can occur at various 
sites in the body, is one of the most common soft tissue sarcomas in both children and adolescents, but is rare in 
adults with a prevalence of less than 1 %. The alveolar subtype of rhabdomyosarcoma (ARMS) is typically charac-
terized by a specific reciprocal chromosomal translocation involving the PAX3 and FKHR or PAX7 and FKHR genes, 
respectively. ARMS is most frequently seen in childhood, and typically affects the sinuses and soft tissue of the 
extremities, with approximately 23 % exhibiting metastasis to the marrow. Non-invasive F-18-fluorodeoxyglucose 
positron-emission tomography (FDG-PET) scans have a high ability to detect lymph nodes, bone, and bone marrow 
involvement in patients with metastatic RMS, often with higher sensitivity and specificity compared with conven-
tional modalities.
Case presentation: Here, we report an unusual case of ARMS confined to the bone marrow in an older adult that 
lacked an identifiable primary tumour using FDG-PET/CT and mimicked a haematological disease with pancytopenia 
but without abnormal findings by FDG-PET/CT. The patient was initially treated with topotecan/cyclophosphamide 
and subsequently switched to vinorelbine. Due to severe toxicity the treatment was discontinued, however after 
7-months follow-up, the patient is still alive with an improved general state of health and only a mild pancytopenia 
with no need for blood transfusions.
Conclusion: Rhabdomyosarcoma can be limited to the bone marrow with no identifiable primary tumour. This case 
shows that the use of a bone marrow biopsy in suspected malignancies affecting the bone marrow is irreplaceable.
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rhabdomyosarcoma, FDG-PET
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Background
Rhabdomyosarcoma (RMS), a malignant tumour of mes-
enchymal origin which can occur at various sites in the 
body, is one of the most common soft tissue sarcomas in 
both children and adolescents, but is rare in adults with 
a prevalence of less than 1 % [1]. The alveolar subtype of 
rhabdomyosarcoma (ARMS) is typically characterized by 
a specific reciprocal chromosomal translocation involv-
ing the PAX3 and FKHR or PAX7 and FKHR genes, 
respectively [2]. ARMS is most frequently seen in 
childhood, and typically affects the sinuses and soft 
tissue of the extremities, with approximately 23 % exhib-
iting metastasis to the marrow [2, 3]. Non-invasive 
F-18-fluorodeoxyglucose positron-emission tomography 
(FDG-PET) scans have a high ability to detect lymph 
nodes, bone, and bone marrow involvement in patients 
with metastatic RMS, often with higher sensitivity and 
specificity compared with conventional modalities [4–6]. 
Here, we report an unusual case of ARMS confined to 
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the bone marrow in an older adult that lacked an identifi-
able primary tumour using FDG-PET/CT and mimicked 
a haematological disease with pancytopenia but without 
abnormal findings by FDG-PET/CT.
Case presentation
A 61-year-old Caucasian female presented to an external 
hospital with a 2  month history of shortness of breath, 
anorexia and fatigue. She had pre-diagnosed obesity, 
liver cirrhosis (non-alcoholic fatty liver disease; Child-
Pugh A), severe osteoporosis and peripheral edema due 
to chronic heart disease. On admission, the patient had 
no fever and no signs of infection, bleeding, haemolysis 
or acute decompensated heart failure. First laboratory 
assessments revealed a pancytopenia grade 2–3 including 
microcytic anaemia with haemoglobin of 7.6 g/dl, white 
blood cells of 1.7 billion/l and platelets of 74 billion/l, as 
well as reduced levels of iron, ferritin and vitamin B12. 
The differential leukocyte count revealed a slight left 
shift, but absence of blasts. Furthermore, electrolytes, 
lactatdehydrogenase (LDH), and serum markers for liver 
and kidney function were in normal ranges. Initial symp-
tomatic treatment management mainly included blood 
transfusions leading to a fast recovery of the patient. To 
rule out a suspected haematological disease a bone mar-
row aspiration was performed, which demonstrated no 
evidence of malignancy. However, since adequate sup-
plementation of iron and vitamin B12 did not improve 
the pancytopenia, and other medical reasons known to 
cause pancytopenia were excluded (e.g. medications, 
infections) bone marrow aspiration was repeated, this 
time including a biopsy. The bone marrow aspiration 
showed no sign of malignancy. Surprisingly, the immu-
nohistological assessment revealed an infiltration (up to 
35 %) of the bone marrow with ARMS (Fig. 1a top panel 
left) with strong positivity for desmin, CD56 and MyF4 
(Fig.  1a bottom panel) and negativity in particular for 
NGFR, TLE1, Melan-A, MITF, HMB45, and S100 (data 
not shown). In addition, genetic analysis of the biopsy by 
reverse transcriptase-polymerase chain reaction (Fig. 1a 
top panel right) and Sanger sequencing (Fig. 1a top panel 
right) detected the PAX3-FKHR gene fusion. The patient 
was immediately referred to our university clinic for fur-
ther evaluation.
Staging and work up of the occult primary tumour via 
whole body FDG-PET (Fig. 1b panel left) showed a sin-
gle site of increased uptake in the right thyroid gland 
with absence of a corresponding lesion in the integrated 
computerised tomography (Fig. 1b top panel right). His-
tological investigation by fine needle aspiration of the 
respective thyroid gland revealed follicular neoplasia. 
Furthermore, adenoma of the right adrenal gland and 
haemangiomas in the 9th and 12th thoracic vertebrae 
(Fig.  1b bottom panel right) were diagnosed via FDG-
PET/CT and were confirmed by magnetic resonance 
imaging (MRI). Otherwise, whole body FDG-PET/CT 
and MRI of the spine and head showed no suspicious 
uptake and/or lesions. In addition, upper gastrointesti-
nal endoscopy and colonoscopy were performed with-
out pathological findings. In summary, diagnosis of an 
ARMS confined to the bone marrow with no identifiable 
primary by FDG-PET/CT and which caused insufficient 
haematopoiesis with the need for regular blood transfu-
sions was made.
Due to co-morbidities and a reduced Eastern Coop-
erative Oncology Group (ECOG) performance status of 
three, we started the patient on topotecan 0.75  mg/m2/
day (days 1–5) and cyclophosphamide 250  mg/m2/day 
(days 1–5) intravenously (i.v.). Chemotherapy-induced 
side effects included increased anorexia, fatigue with 
ECOG 4, and haematological toxicity with pancytope-
nia Common Terminology Criteria for Adverse Events 
(CTCAE) grade 3–4. Temporary, increased rates of trans-
fusion (red blood cells and platelets) were necessary, as 
well as the application of iv. antibiotics and granulocyte-
colony stimulating factor (G-CSF) due to recurrent fever-
in-neutropenia. After the third cycle of chemotherapy, 
bone marrow aspiration and biopsy were repeated show-
ing maturing trilineage haematopoiesis with no signs of 
RMS tumour cells. Due to the significant level of high-
grade toxicities related to the applied combination chem-
otherapy and the significant response already achieved 
we decided to apply monotherapeutic vinorelbine 30 mg/
m2/d d1 + d8 i.v. (max 60 mg abs./d; q3w) as a consoli-
dation therapy. After the first cycle of vinorelbine, the 
patient developed muscle and joint pain, nausea/emesis, 
as well as autonomic neuropathy causing severe consti-
pation. Subsequently, the acute side effects were treated 
adequately, and follow-up care was introduced.
At present, after a 7-months follow-up, the patient 
is still alive with an improved general state of health 
and only a mild pancytopenia with no need for blood 
transfusions.
Conclusion
Rhabdomyosarcoma is an aggressive type of sarcoma 
arising in the soft tissues of the body, like muscles, ten-
dons, and connective tissues [1, 3]. A multimodal treat-
ment including multiagent chemotherapy, radiotherapy, 
and surgery, is standard of care for this disease, and can 
lead to a relatively high rate of cure in young patients 
with local or regional RMS [1, 3, 7]. Improvements in 
risk stratifications have allowed the treatment assign-
ment of pediatric patients in different therapeutic trials, 
leading to an increase of up to 70 % in 5 year survival [1, 
3, 7]. However, for adult patients, in great part due to 
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Fig. 1 a Histological and genetic characteristics of bone marrow infiltrating cells. Top left Infiltration of the bone marrow by medium to large atypi-
cal cells (×40), right top corner (×100); top right Gelelectrophoresis of PAX/FKHR RT-PCR including positive and negative controls for PAX7- und PAX3-
FKHR fusions in two dilutions (neat and 1:50), below results of Sanger sequencing; bottom panel the atypical cells express desmin, CD56 and MyF4. 
b Left panel Whole body positron emission tomography (PET-CT); top right panel PET-CT indicating one single increased uptake in the right thyroid 
gland revealing follicular neoplasia; bottom right panel haemangioma in the 9th thoracic vertebrae
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rarity of the disease and the lack of clear guidelines for 
standard treatment, as well as increased prevalence of 
advanced presentations, clinical outcome is still dismal. 
The presence of metastases is one of the most adverse 
prognostic factor in RMS, and bone marrow is a frequent 
site of tumour dissemination, especially in ARMS [8]. 
Therefore, with FDG-PET/CT the treatment algorithm 
has improved through more accurate staging including 
greater precision in detecting lymph node disease and 
distant metastases compared with anatomic imaging 
alone [4–6]. Moreover this case illustrates that frequently 
bone marrow smears alone are not sufficient to diagnose 
tumour infiltrations of the bone marrow and therefore 
a trephine is necessary in any unexplained pancytope-
nia and will not be replaced by bone marrow aspiration/
cytology alone. Furthermore recent emerging data show 
that new techniques such as whole body diffusion weight 
(DW)-MRI alongside with molecular and genetic analy-
sis could lead the way to further guide clinical decisions 
[9].
To the best of our knowledge, we present the first case 
of an adult patient with ARMS limited to the bone mar-
row with no identifiable primary tumour by FDG-PET/
CT scan. We report this case for its rarity, occurrence in 
an adult with complete absence of a primary of ARMS, 
and to increase awareness in the diagnostic, as well as in 
the staging evaluation for the irreplaceable use of a bone 
marrow biopsy in suspected malignancies affecting the 
bone marrow.
Consent
Written informed consent was obtained from the patient 
for publication of this case report and any accompany-
ing images. A copy of the written consent is available for 
review by the Editor of this journal.
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